



## 8<sup>th</sup> Meeting of the bOPV Cessation Team (BOCeT)

*Hybrid Virtual/In Person in Geneva*

*Room: M305*

*MS Teams Link: [Hyperlink](#)*

*July 1-2, 2024*

---

### Objective of the meeting:

To formulate asks for discussion and eventual endorsement by SAGE WG and full SAGE in the fall 2024

### Day 1 (July 1):

9:00 – 9:15	Welcome, opening remarks, introductions; and expected outcomes of the meeting	BOCeT Chairs
9:15 – 9:30	Note on overarching principles of bOPV cessation, triggers, enablers of success; and primer on definitions	O. Mach
9:30 – 10:00	Summary of recommendations from “Lessons learned” and alignment with BOCeT	R. Lopez, C. Estivariz
10:00 – 10:15	Introduction to 4 enablers of successful cessation	O. Mach
	<ol style="list-style-type: none"><li>1. Reaching High population immunity</li><li>2. Outbreak response capacity</li><li>3. Verified absence of cVDPVs</li><li>4. Sufficient vaccines</li></ol>	
10:15 – 10:30	Break	

10:30 – 13:30 **Reaching High population immunity**

***Key output: Formulate asks for SAGE endorsement that will enable reaching and sustaining high population immunity pre-cessation***

1) Presentations from modelling groups coordinated by SAM (Subgroup on Analytics and Modelling)

2) Routine Immunization

Session leads: D. Chang-Blanc,  
A. Ramirez Gonzalez

3) Pre-cessation SIAs

Session lead: C. Estivariz

13:30 – 14:00 LUNCH

14:00 – 15:00 **Outbreak response capacity**

Session lead: K. Djibaoui

***Key output: Formulate asks for SAGE endorsement on outbreak response SOPs for the post-cessation era***

15:00 – 15:30 Break

15:30 – 16:00 Discussion and end of day 1

## **Day 2 (July 2):**

9:00 – 10:30 **Verified absence of persistent cVDPVs**

Session lead: Z. Wadood

***Key output: Formulate asks for SAGE endorsement on surveillance capacity to verify the absence of persistent cVDPVs prior to bOPV cessation and to detect potential new outbreaks post-cessation; to define the role of GCC in making official the verification of absence of cVDPVs.***

10:30 – 12:00 **Sufficient Vaccines** (for pre and post cessation era)

Session lead: A. Ottosen, I. Lewis

***Key output: Formulate asks for SAGE endorsement on securing sufficient vaccine supply for the pre-cessation era SIAs and vaccine stock for potential post-cessation outbreak response.***

CLOSED SESSION for BOCeT Management, Session Leads and Liaisons

12:00 – 13:30 Formulation of asks to SAGE including specific enablers of successful cessation

Session lead: R. Lopez